BioCentury
ARTICLE | Top Story

PCSK9 inhibitors continue neck-and-neck

March 17, 2015 12:53 AM UTC

In newly published analyses, the PCSK9 inhibitors Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) and Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed early evidence of reducing cardiovascular (CV) events in patients with hypercholesterolemia.

Post hoc analyses from studies of Repatha and Praluent, both human mAbs against PCSK9 (proprotein convertase subtilisin/kexin type 9), were published simultaneously in the New England Journal of Medicine and presented at the American College of Cardiology's annual meeting. In an accompanying Northwestern University wrote that "it would be premature to endorse these drugs for widespread use before the ongoing randomized trials" designed to measure CV outcomes read out. Amgen expects data in 2017 from its multi-year CV outcomes trial of Repatha; Sanofi and Regeneron intend to complete their CV outcomes trial of Praluent by YE17. ...